The evolution of bladder preservation strategies has historically paralleled advances in systemic therapy for muscle-invasive bladder cancer (MIBC). Radiosensitizing agents incorporated into ...

ESMO 2025 final results of PRESTO (AFT-19), phase III trial of combined androgen blockade in patients with high-risk, biochemically relapsed prostate cancer.

(UroToday.com) The 2026 Advanced Prostate Cancer Consensus Conference (APCCC) meeting featured a management of metastatic hormone sensitive prostate cancer (mHSPC) session and a presentation by Dr.

Jason Efstathiou discusses the use of genomic classifiers and AI-based tools in personalizing radiation therapy for prostate cancer. Decipher®, a 22-gene expression classifier, assesses tumor biology ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...

(UroToday.com) The 2025 European Society for Medical Oncology (ESMO) Annual Congress was host to a presidential symposium. Dr. Jun Guo presented the results of a trial of disitamab vedotin + ...

Randy A. Vince Jr., Ralph Jiang, Ji Qi, Jeffrey J. Tosoian, Rebecca Takele, Felix Y. Feng, Susan Linsell, Anna Johnson, Sughand Shetty, Patrick Hurley, David C ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

(UroToday.com) The 2025 PSMA and Beyond annual meeting featured new developments in genitourinary radioligand therapy session and a presentation by Dr. Robert Flavell discussing STEAP1, DLL3, and CD46 ...

(UroToday.com) The 2024 European Association of Urology (EAU) annual meeting featured a session on metastatic prostate cancer, and a presentation by Dr. Thomas Zilli discussing 24-month toxicity ...

(UroToday.com) The 2026 SESAUA annual meeting featured a prostate cancer session and presentation by Dr. Murilo de Almeida Luz discussing PSA and alkaline phosphatase decline in the EORTC PEACE-3 ...